HU9403310D0 - Gaba and l-glutamic acid analogs for antiseizure treatment - Google Patents

Gaba and l-glutamic acid analogs for antiseizure treatment

Info

Publication number
HU9403310D0
HU9403310D0 HU9403310A HU9403310A HU9403310D0 HU 9403310 D0 HU9403310 D0 HU 9403310D0 HU 9403310 A HU9403310 A HU 9403310A HU 9403310 A HU9403310 A HU 9403310A HU 9403310 D0 HU9403310 D0 HU 9403310D0
Authority
HU
Hungary
Prior art keywords
gaba
glutamic acid
acid analogs
compound
treatment
Prior art date
Application number
HU9403310A
Other languages
English (en)
Other versions
HU222339B1 (hu
HUT71522A (en
Inventor
Richard B Silverman
Ryszard Andruszkiewicz
Po-Wai Yuen
Denis Martin Sobieray
Lloyd Charles Franklin
Mark Alan Schwindt
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU9403310(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Northwestern filed Critical Univ Northwestern
Priority to HU9702482A priority Critical patent/HU222776B1/hu
Publication of HU9403310D0 publication Critical patent/HU9403310D0/hu
Publication of HUT71522A publication Critical patent/HUT71522A/hu
Publication of HU222339B1 publication Critical patent/HU222339B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
HU9403310A 1992-05-20 1993-05-18 S-(+)-4-amino-3-(2-metil-propil)-butánsav, és gyógyászati szempontból elfogadható sói, ezeket tartalmazó gyógyászati készítmények, valamint az (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállítása HU222339B1 (hu)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU9702482A HU222776B1 (hu) 1992-05-20 1993-05-18 (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88608092A 1992-05-20 1992-05-20
PCT/US1993/004680 WO1993023383A1 (en) 1992-05-20 1993-05-18 Gaba and l-glutamic acid analogs for antiseizure treatment

Publications (3)

Publication Number Publication Date
HU9403310D0 true HU9403310D0 (en) 1995-02-28
HUT71522A HUT71522A (en) 1995-12-28
HU222339B1 HU222339B1 (hu) 2003-06-28

Family

ID=25388336

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9702482A HU222776B1 (hu) 1992-05-20 1993-05-18 (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása
HU9403310A HU222339B1 (hu) 1992-05-20 1993-05-18 S-(+)-4-amino-3-(2-metil-propil)-butánsav, és gyógyászati szempontból elfogadható sói, ezeket tartalmazó gyógyászati készítmények, valamint az (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállítása

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9702482A HU222776B1 (hu) 1992-05-20 1993-05-18 (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása

Country Status (22)

Country Link
EP (1) EP0641330B1 (hu)
JP (2) JP3856816B2 (hu)
KR (1) KR950701625A (hu)
AT (1) ATE207052T1 (hu)
AU (1) AU677008B2 (hu)
CA (1) CA2134674C (hu)
CZ (1) CZ286106B6 (hu)
DE (2) DE69330949T2 (hu)
DK (1) DK0641330T3 (hu)
ES (1) ES2165857T3 (hu)
FI (1) FI945426A (hu)
HK (1) HK1011022A1 (hu)
HU (2) HU222776B1 (hu)
LU (1) LU91112I2 (hu)
NL (1) NL300164I2 (hu)
NO (1) NO944370L (hu)
NZ (1) NZ253459A (hu)
PT (1) PT641330E (hu)
RU (2) RU2140901C1 (hu)
SG (1) SG48288A1 (hu)
SK (1) SK283281B6 (hu)
WO (1) WO1993023383A1 (hu)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
NZ290050A (en) * 1994-07-27 1999-08-30 Warner Lambert Co Treatment of anxiety with gabapentin
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
BR9712651A (pt) * 1996-10-23 1999-10-26 Warner Lambert Co ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
ATE311867T1 (de) 1997-09-08 2005-12-15 Warner Lambert Co Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
PL204921B1 (pl) * 1998-05-15 2010-02-26 Warner Lambert Co Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania
PT1121114E (pt) * 1998-10-16 2007-03-30 Warner Lambert Co Utilização de análogos gaba para a produção de um medicamento para o tratamento da mania e da doença bipolar
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
ES2341059T3 (es) * 1999-04-08 2010-06-14 Warner-Lambert Company Llc Tratamiento de la incontinencia.
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
CN1196671C (zh) * 1999-06-10 2005-04-13 沃尼尔·朗伯公司 单和双取代的3－丙基－γ－氨基丁酸
WO2002022622A2 (en) 2000-09-13 2002-03-21 Georgetown University Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
US20030225149A1 (en) * 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
NZ545884A (en) 2003-09-11 2010-01-29 Xenoport Inc Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
CA2710152A1 (en) * 2007-12-26 2009-07-02 Generics (Uk) Limited Processes to pregabalin
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
US8062870B2 (en) 2008-01-25 2011-11-22 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2110372A1 (en) 2008-04-16 2009-10-21 Chemo Ibérica, S.A. Intermediates for the preparation of Pregabalin and process for their preparation
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
ES2362913B1 (es) 2009-12-24 2012-05-24 Moehs Iberica S.L. Nuevo método para la preparación de (s)-pregabalina.
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
LT2548871T (lt) 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cikloalkilpakeistieji imidazolo dariniai
CN102884053B (zh) 2010-03-18 2016-03-02 第一三共株式会社 环丙烷甲酸衍生物
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
EP2415460A1 (de) 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US8212072B2 (en) 2010-08-13 2012-07-03 Divi's Laboratories, Ltd. Process for the preparation of pregabalin
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2527319A1 (en) 2011-05-24 2012-11-28 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of pregabalin and co-formers in the treatment of pain
WO2013100873A1 (en) 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
ES2423254B1 (es) 2012-02-15 2014-03-26 Laboratec, S.L. Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2948139B1 (en) 2013-01-28 2019-06-12 Lopez, Hector, L. Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
EP3082782A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CN105873580B (zh) 2013-12-17 2020-08-25 埃斯蒂维制药有限公司 加巴喷丁类化合物与σ受体配体的组合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
EP3793974A4 (en) 2018-05-14 2022-05-04 Xgene Pharmaceutical Inc CRYSTALLINE FORMS OF THE 1-(ACYLOXY)-ALKYL CARBAMATE DRUG CONJUGATE OF NAPROXEN AND PREGABALIN
DE202018105573U1 (de) 2018-09-27 2018-10-19 Laboratec Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4840460B1 (hu) * 1969-02-05 1973-11-30
US4173541A (en) * 1978-06-05 1979-11-06 Cincinnati Milacron Chemicals Inc. Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
US4814342A (en) * 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) * 1990-10-19 1993-05-14 한국과학기술연구원 d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
WO1992009560A1 (en) * 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) * 1992-01-30 1993-03-30 Warner-Lambert Company Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

Also Published As

Publication number Publication date
RU2140901C1 (ru) 1999-11-10
FI945426A0 (fi) 1994-11-18
FI945426A (fi) 1994-11-18
LU91112I2 (fr) 2004-12-06
EP0641330B1 (en) 2001-10-17
RU94046105A (ru) 1997-06-20
HU222776B1 (hu) 2003-10-28
HU222339B1 (hu) 2003-06-28
PT641330E (pt) 2002-03-28
EP0641330A1 (en) 1995-03-08
HU9702482D0 (en) 1998-03-02
DE122004000039I1 (de) 2006-05-18
AU677008B2 (en) 1997-04-10
NO944370L (no) 1994-11-21
DE122004000039I2 (de) 2006-06-29
NL300164I1 (nl) 2005-01-03
NL300164I2 (nl) 2005-02-01
HK1011022A1 (en) 1999-07-02
WO1993023383A1 (en) 1993-11-25
CZ284994A3 (en) 1995-03-15
DE69330949T2 (de) 2002-04-04
AU4379493A (en) 1993-12-13
DK0641330T3 (da) 2001-12-03
KR950701625A (ko) 1995-04-28
SG48288A1 (en) 1998-04-17
CA2134674A1 (en) 1993-11-25
CA2134674C (en) 2004-12-21
HUT71522A (en) 1995-12-28
NZ253459A (en) 1997-03-24
JP4297814B2 (ja) 2009-07-15
EP0641330A4 (en) 1997-05-28
JP3856816B2 (ja) 2006-12-13
JPH07508288A (ja) 1995-09-14
DE69330949D1 (de) 2001-11-22
ATE207052T1 (de) 2001-11-15
CZ286106B6 (cs) 2000-01-12
ES2165857T3 (es) 2002-04-01
JP2004238398A (ja) 2004-08-26
NO944370D0 (no) 1994-11-16
SK283281B6 (sk) 2003-05-02
SK139594A3 (en) 1995-05-10

Similar Documents

Publication Publication Date Title
SG48288A1 (en) Gaba and l-glutamic acid analogs for antiseizure treatment
MX9102241A (es) Analogos de gaba y de acido l-glutamico para tratamiento contra ataques.
IL110216A (en) Valproic acid amide derivatives and pharmaceutical compositions containing them
EP0484094A3 (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
HUT52036A (en) Process for producing optically active amino-acides and theyr intermediates
MX9302970A (es) Analogos de acido l-glutamico y gaba para tratamiento anti-ataque.
HUT70219A (en) 1-phenylpyrrolidone derivatives, intermediates for producing them and producing them

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20030410

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: PREGABALIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/04/279/001-025 20040706

Spc suppl protection certif: S0400048

Filing date: 20041026

Expiry date: 20130518

Extension date: 20180518